“Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT / Polverelli, Nicola; Hernandez-Boluda, Juan Carlos; Onida, Francesco; Gurnari, Carmelo; Raj, Kavita; Czerw, Tomasz; Kenyon, Michelle; Robin, Marie; Sockel, Katja; Ruggeri, Annalisa; Sánchez-Ortega, Isabel; Arber, Daniel A.; Arcaini, Luca; Duarte, Fernando Barroso; Battipaglia, Giorgia; Chalandon, Yves; Ciceri, Fabio; Cross, Nicholas C.P.; Drozd-Sokolowska, Joanna; Funke, Vaneuza Araújo Moreira; Gagelmann, Nico; Gangat, Naseema; Gotlib, Jason; Guglielmelli, Paola; Harrison, Claire N.; Hobbs, Gabriela S; Jain, Tania; Khoury, Joseph D.; Kiladjian, Jean-Jacques; Kröger, Nicolaus; Malcovati, Luca; Martino, Massimo; Mesa, Ruben; Orazi, Attilio; Padron, Eric; Palandri, Francesca; Passamonti, Francesco; Patnaik, Mrinal M.; Pemmaraju, Naveen; Radia, Deepti H.; Reiter, Andreas; Russo, Domenico; Scheid, Christof; Tefferi, Ayalew; Vannucchi, Alessandro M.; Wiseman, Daniel Howard; Yakoub-Agha, Ibrahim; McLornan, Donal P. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 145:(2025), pp. 2561-2573. [10.1182/blood.2024028000]
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Guglielmelli, Paola;Palandri, Francesca;Vannucchi, Alessandro M.;
2025
Abstract
“Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.File | Dimensione | Formato | |
---|---|---|---|
blood.2024028000.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
960.81 kB
Formato
Adobe PDF
|
960.81 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.